Classification of thyroid hormone receptor agonists and antagonists using statistical learning approaches
1School of Life Science, Linyi University, Linyi, 276000, China. yu100288@163.com.
Molecular Diversity
|July 18, 2018
Summary
This study developed in silico models to predict thyroid hormone receptor (TR) agonists and antagonists. Support Vector Machine (SVM) and Random Forest (RF) models showed high accuracy, proving useful for classifying TR-binding ligands.
Area of Science:
- Computational chemistry
- Pharmacology
- Bioinformatics
Background:
- Thyroid hormone receptors (TRs) play crucial roles in metabolism and development.
- Accurate prediction of TR agonists and antagonists is vital for drug discovery and toxicological assessment.
- Existing methods for classifying TR-binding ligands have limitations.
Purpose of the Study:
- To develop and validate in silico models for predicting thyroid hormone receptor (TR) agonists and antagonists.
- To compare the performance of C4.5, Random Forest (RF), and Support Vector Machine (SVM) algorithms for this classification task.
- To establish reliable computational tools for identifying TR-binding ligands.
Main Methods:
- Utilized a dataset of 258 compounds for model development.
- Employed C4.5, Random Forest (RF), and Support Vector Machine (SVM) statistical methods.
- Validated model performance using fivefold cross-validation and an independent external test set.
Main Results:
- The C4.5 model demonstrated moderate performance with an average accuracy of 83.1% on the test set.
- The RF model achieved an average prediction accuracy of 84.0% (cross-validation) and 87.1% (external validation).
- The SVM model exhibited superior performance with overall and external prediction accuracies of 96.6% and 97.2%, respectively.
Conclusions:
- The developed in silico models, particularly RF and SVM, are reliable for classifying TR-binding ligands.
- These computational models serve as valuable tools for predicting TR agonists and antagonists.
- The findings support the utility of machine learning in drug discovery and chemical safety assessment.
Related Concept Videos
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.5K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.5K
Functions of Thyroid Hormones
5.7K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
5.7K
Synthesis and Regulation of Thyroid Hormones
7.9K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.9K
Adrenergic Agonists: Therapeutic Classification
1.7K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.7K
Glucagon-like Receptor Agonists
985
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
985


